Moses et al. [190] have demonstrated the feasibility of targeting the HSP40/HSP70 chaperone axis to treat castration-resistant prostate cancer (CRPR) that is insusceptible to antiandrogen therapy. Here, HSPA1A is linked to prostate cancer.